Authors
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
ADT Treatment Considerations and Unmet Needs in Prostate CancerExperts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Latest:
Insights on Perirectal Spacing in Prostate CancerIn the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.
Latest:
Clinical Pearls for Community Urologists Treating Patients with MIBCDr Chamie shares advice for community urologists treating patients with MIBC.
Latest:
PSMA PET-CT Imaging: Impact on Real-World Diagnosis and Management of Prostate CancerIn this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.
Latest:
US Urology Partners Names Healthcare Visionary Raoul S. Concepcion, MD, as Chief Science OfficerConcepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Does varicocele affect prostate cancer outcomes?"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.
Latest:
Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging ResultsTony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
Latest:
Arvin K. George, MD, provides update on the PRESERVE trialThe PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.
Latest:
PINNACLE trial aims to confirm pilot success with BPH drug-coated balloon catheterThe drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
Latest:
Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says Sandip M. Prasad, MD.
Latest:
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Latest:
Tim Richardson, MD, on genetic testing in the era of targeted therapies“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R. Cooperberg, MD, MPH.
Latest:
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
Latest:
Addressing Remaining Unmet Needs in mCRPCPanelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
Latest:
Madison Wahlen on navigating the impact of the BCG shortage“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen.
Latest:
Urologic Consultants has joined Solaris HealthLeading West Michigan practice now affiliated with nation’s largest urological healthcare management company
